Overall, these results recapitulate the in vitro observations and suggest that AKR1C1 depletion could render cancer cells more sensitive to ferroptosis and the combination of targeting AKR1C1 with ferroptosis inducers might represent a promising strategy for ECC treatment. The gene discussed is AKR1C1; the disease is cancer.